Chronic graft versus host disease

13 trials 7 recruiting MedDRA PT
13 Registered trials
7 Recruiting
8 Unique sponsors
9 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 4
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
JAK inhibitor 1 substance
Monoclonal antibody (immune) 1 substance
Kinase inhibitor 1 substance
HDAC inhibitor 1 substance
BTK inhibitor 1 substance
Corticosteroid 1 substance
Phase III: 3 Phase II: 6 Phase I/II: 2 Phase IV: 1 Other: 1

Filter these 13 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 13 trials

Phase III

3 trials
  • Incyte Corp. Commercial
    AXATILIMAB
    2023-510292-65-00 8 countries 2025 n=201
    Recruiting
  • Incyte Corp. Commercial
    AXATILIMAB
    2024-518973-32-00 14 countries 2025 n=283
    Recruiting
  • Sanofi-Aventis Research & Development Commercial
    BELUMOSUDIL MESILATE
    2023-505394-32-00 13 countries 2025 n=157 Orphan
    Ended

Phase II

6 trials
  • Incyte Corp. Commercial
    ITACITINIB
    2022-501661-47-00 6 countries 2023 n=12 Orphan
    Ended
  • Incyte Corp. Commercial
    AXATILIMAB; RUXOLITINIB
    2022-502168-19-00 4 countries 2024 n=70
    Ended
  • Incyte Corp. Commercial
    AXATILIMAB
    2025-521849-25-00 4 countries 2026 n=42
    Recruiting
  • Syndax Pharmaceuticals Inc. Commercial
    AXATILIMAB
    2024-512978-99-00 6 countries 2021 n=67
    Ended
  • Medical Center - University Of Freiburg Academic
    METHOXSALEN; RUXOLITINIB
    2023-507754-33-00 2 countries 2025 n=40
    Recruiting
  • Medical Center - University Of Freiburg Academic
    BELUMOSUDIL MESILATE
    2025-521940-39-00 1 country 2026 n=24
    Recruiting

Phase I/II

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB; PREDNISONE
    2023-507330-24-00 5 countries 2019 n=14
    Ended
  • Sanofi-Aventis Recherche & Developpement Commercial
    BELUMOSUDIL MESILATE
    2024-511508-18-00 6 countries 2026 n=23 Orphan
    Recruiting

Phase IV

1 trial
  • Novartis Pharma Services AG Commercial
    PANOBINOSTAT; RUXOLITINIB; SIREMADLIN
    2024-515283-31-00 4 countries 2015 n=33 Orphan
    Ended

Other

1 trial
  • Qurient Co. Ltd. Commercial
    IMP not specified
    2025-522680-14-00 1 country 2025 n=16
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 5 Phase II, Phase III 3
Medical Center - University Of Freiburg Academic 2 Phase II 2
Qurient Co. Ltd. Commercial 1 Other 1
Syndax Pharmaceuticals Inc. Commercial 1 Phase II 0
Sanofi-Aventis Research & Development Commercial 1 Phase III 0
Novartis Pharma Services AG Commercial 1 Phase IV 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I/II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase I/II 1
New trials by year
2019
1
2021
1
2023
1
2024
1
2025
5
2026
3
← All indication landscapes